- Title: Subtitle
- Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma
- Creators
- Yousef Zakharia - University of IowaOlivier Rixe - Gabrail Cancer CenterJohn Harris Ward - University of UtahJoseph J. Drabick - Penn State Milton S. Hershey Medical CenterMontaser F. Shaheen - New Mexico Cancer CenterMohammed M. Milhem - University of IowaDavid Munn - Augusta University HealthEugene Paul Kennedy - NewLink GeneticsNicholas N. Vahanian - NewLink GeneticsCharles J. Link - NewLink GeneticsRobert R. McWilliams - Mayo Clinic Rochester, MN
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.9512-9512
- DOI
- 10.1200/JCO.2018.36.15_suppl.9512
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363173002771
Abstract
Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma
Journal of clinical oncology, Vol.36(15_suppl), pp.9512-9512
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.9512
Details
Metrics
8 Record Views